Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs T3D 959 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors T3D Therapeutics
  • Most Recent Events

    • 06 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
    • 06 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top